Characteristics of responding patients (CR and CRp)
Patient no. . | Age, y/sex . | Diagnosis . | Karyotype . | Prior therapy . | CRD1, mos . | Response (dose, mg/m2per day*)/duration, mos . | No. of courses to response . |
|---|---|---|---|---|---|---|---|
| 3 | 74/M | AML | Diploid | GO + IL-11 | 13.8 | CR (15)/7.4 | 1 |
| 4 | 53/F | AML | Diploid | FA + GO + CSA | 14.8 | CRp (22.5)/1.7 | 1 |
| 7 | 62/F | AML | Diploid | I + HDAC | 12.4 | CRp (30)/1.9 | 1 |
| 11 | 59/M | AML | Diploid | I + HDAC | 9.5 | CR (40)/2.9 | 1 |
| 17 | 71/M | AML | Tetraploidy | IA | 4.8 | CR (40)/5+ | 1 |
| 18 | 47/M | AML | Diploid | IA | 0 | CR (40)/6+ | 2 |
| 20 | 39/M | AML | Inv(16) | FLAG | 17.4 | CR (40)/5+ | 1 |
| 24 | 72/M | RAEB | Inv(3),del(13) | IA | 9.3 | CRp (40)/3+ | 1 |
| 25 | 66/F | AML | Diploid | IA | 10.5 | CRp (40)/5+ | 1 |
| 27 | 65/F | AML | -5/-7 | IA | 0 | CR (40)/0.5 (died in CR) | 1 |
| 29 | 74/M | AML | -5/-7 | IA | 7.6 | CR (40)/3+ | 1 |
| 30 | 56/M | RAEBT | Del(20) | IA + IL-11 | 6.5 | CRp (40)/3 | 1 |
Patient no. . | Age, y/sex . | Diagnosis . | Karyotype . | Prior therapy . | CRD1, mos . | Response (dose, mg/m2per day*)/duration, mos . | No. of courses to response . |
|---|---|---|---|---|---|---|---|
| 3 | 74/M | AML | Diploid | GO + IL-11 | 13.8 | CR (15)/7.4 | 1 |
| 4 | 53/F | AML | Diploid | FA + GO + CSA | 14.8 | CRp (22.5)/1.7 | 1 |
| 7 | 62/F | AML | Diploid | I + HDAC | 12.4 | CRp (30)/1.9 | 1 |
| 11 | 59/M | AML | Diploid | I + HDAC | 9.5 | CR (40)/2.9 | 1 |
| 17 | 71/M | AML | Tetraploidy | IA | 4.8 | CR (40)/5+ | 1 |
| 18 | 47/M | AML | Diploid | IA | 0 | CR (40)/6+ | 2 |
| 20 | 39/M | AML | Inv(16) | FLAG | 17.4 | CR (40)/5+ | 1 |
| 24 | 72/M | RAEB | Inv(3),del(13) | IA | 9.3 | CRp (40)/3+ | 1 |
| 25 | 66/F | AML | Diploid | IA | 10.5 | CRp (40)/5+ | 1 |
| 27 | 65/F | AML | -5/-7 | IA | 0 | CR (40)/0.5 (died in CR) | 1 |
| 29 | 74/M | AML | -5/-7 | IA | 7.6 | CR (40)/3+ | 1 |
| 30 | 56/M | RAEBT | Del(20) | IA + IL-11 | 6.5 | CRp (40)/3 | 1 |
CRD1 indicates first remission duration (0 indicates primary refractory to induction therapy); GO, gemtuzumab ozogamicin (mylotarg); IL-11, interleukin-11; FA, fludarabine, ara-C; CSA, cyclosporine A; I, idarubicin; HDAC, high-dose ara-C; IA, idarubicin and ara-C; FLAG, fludarabine, HDAC, G-CSF; inv(16), inversion of chromosome 16; inv(3), inversion of chromosome 3; del, deletion; -5/-7, monosomy of chromosomes 5 and 7; CR, complete remission; CRp, complete remission without platelet recovery ≥ 100 × 109/L.
Dose of clofarabine.